Table 2.
The vaccine comparators and schedules used in each economic evaluation
| Vaccine | Number of studies—no vaccine | Number of studies—type of vaccine | Number of studies—vaccine programb | Funding and target populationc |
|---|---|---|---|---|
| Escherichia coli | 1 (0/1)a | – | – | Private |
| Group B Streptococcus | 1 (1/1) | – | – | Not yet available |
| Hepatitis A | – | 1 | – | Private |
| Hepatitis B | 5 (3/5) | – | 1 | Public-universal |
| Hepatitis C | 1 (1/1) | – | – | Not yet available |
| Herpes Zoster | 2 (2/2) | – | – | Private |
| HPV | 7 (7/7) | 4 | 2 | Public-universal |
| Influenza—(seasonal and H1N1) | 6 (5/6) | 1 | 4 | Public-Universal/targeted |
| Measles or Mumps or MMR | 2 (2/2) | – | 3 | Public-universal |
| Meningococcal A, C, Y, W135 | 2 (1/2) | 2 | 1 | Public-universal |
| Meningitis B | 1 (0/1) | – | – | Public-targeted/private |
| Pertussis | 1 (1/1) | 2 | 2 | Public-universal |
| Pneumococcal | 4 (4/4) | 4 | 1 | Public-universal |
| Rabies | 1 (1/1) | – | – | Private |
| Rotavirus | 2 (2/2) | 2 | – | Public-universal |
| Tetanus | 1 (1/1) | – | – | Public-universal |
| Varicella | 3 (2/3) | – | 1 | Public-universal |
a Ratio represents the number of studies that found the vaccine was cost-effective compared to no vaccine
b For example: schedule, booster dose, universal vs. targeted
c Funding and target population for vaccines as of March 2015